Bank Julius Baer & Co. Ltd Zurich trimmed its stake in Chimerix, Inc. (NASDAQ:CMRX) by 23.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,981 shares of the biopharmaceutical company’s stock after selling 7,019 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Chimerix were worth $111,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CMRX. AQR Capital Management LLC bought a new position in shares of Chimerix in the 3rd quarter worth $479,000. Boothbay Fund Management LLC acquired a new position in Chimerix during the 3rd quarter valued at about $378,000. Opaleye Management Inc. increased its position in Chimerix by 3.0% during the 4th quarter. Opaleye Management Inc. now owns 3,956,500 shares of the biopharmaceutical company’s stock valued at $19,110,000 after buying an additional 115,000 shares in the last quarter. JPMorgan Chase & Co. increased its position in Chimerix by 234.6% during the 4th quarter. JPMorgan Chase & Co. now owns 144,463 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 101,287 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Chimerix during the 1st quarter valued at about $166,000. 45.41% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on the company. Wedbush assumed coverage on Chimerix in a research report on Wednesday, March 31st. They set an “outperform” rating and a $21.00 target price on the stock. Jonestrading reaffirmed a “buy” rating and set a $10.00 target price on shares of Chimerix in a research report on Friday, January 8th. HC Wainwright upped their target price on Chimerix from $7.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 11th. They noted that the move was a valuation call. Zacks Investment Research downgraded Chimerix from a “buy” rating to a “hold” rating in a research note on Friday, April 2nd. Finally, Jefferies Financial Group assumed coverage on Chimerix in a research note on Wednesday, March 31st. They set a “buy” rating and a $21.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $15.80.
Shares of CMRX opened at $8.75 on Thursday. Chimerix, Inc. has a 52 week low of $1.37 and a 52 week high of $11.57. The company has a market capitalization of $749.69 million, a price-to-earnings ratio of -15.35 and a beta of 1.88. The stock’s 50-day moving average price is $9.73 and its 200-day moving average price is $6.22.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.59 million. Chimerix had a negative return on equity of 36.57% and a negative net margin of 321.31%. Equities research analysts expect that Chimerix, Inc. will post -0.71 EPS for the current fiscal year.
Chimerix, Inc, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients.
Recommended Story: What is a put option?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.